1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags: BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags: Junshi, Impact, Establish, Joint Venture, […]Read More
Shots: mAbxience will produce ~200M + doses of AZD1222 and will supply it to all Latin American countries, except Brazil The company will produce API in its facility located in Garín (Argentina) and will send it to Mexico to complete the production and filling process. AstraZeneca will transfer its technology to the Garín plant shortly, […]Read More
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence providers are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More
The development project involves investment of $40M and doubled its production capacity and will export biosimilar in Central America, South America, Africa, Asia and the Middle East The plant will currently have 162 employees with 50 new jobs, and it is expected to generate another 50 positions over the coming years work according to GMP […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
